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Background: Monocyte-to-osteoclast conversion is a unique terminal differentiation process that is exacerbated
in rheumatoid arthritis and bone metastasis. The mechanisms implicated in upregulating osteoclast-specific genes
involve transcription factors, epigenetic regulators and microRNAs (miRNAs). It is less well known how downregulation
of osteoclast-inappropriate genes is achieved.
Results: In this study, analysis of miRNA expression changes in osteoclast differentiation from human primary monocytes
revealed the rapid upregulation of two miRNA clusters, miR-212/132 and miR-99b/let-7e/125a. We demonstrate that
they negatively target monocyte-specific and immunomodulatory genes like TNFAIP3, IGF1R and IL15. Depletion of these
miRNAs inhibits osteoclast differentiation and upregulates their targets. These miRNAs are also upregulated in other
inflammatory monocytic differentiation processes. Most importantly, we demonstrate for the first time the direct
involvement of Nuclear Factor kappa B (NF-κB) in the regulation of these miRNAs, as well as with their targets, whereby
NF-κB p65 binds the promoters of these two miRNA clusters and NF-κB inhibition or depletion results in impaired
upregulation of their expression.
Conclusions: Our results reveal the direct involvement of NF-κB in shutting down certain monocyte-specific genes,
including some anti-inflammatory activities, through a miRNA-dependent mechanism for proper osteoclast
differentiation.Background
The successful generation of differentiated cell types from
their progenitors depends on the highly coordinated regu-
lation of gene expression by transcription factors, epigen-
etic enzymes, and small non-coding RNAs, of which
microRNAs (miRNAs) are the best studied. These regu-
late gene expression through sequence complementarity
with their target mRNAs by mediating their decay or
interfering with their translation [1]. miRNAs are known
to have a major role in cell differentiation. However, their* Correspondence: eballestar@idibell.cat
†Equal contributors
1Chromatin and Disease Group, Cancer Epigenetics and Biology Programme
(PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908 L’Hospitalet
de Llobregat, Barcelona, Spain
Full list of author information is available at the end of the article
© 2015 de la Rica et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.specific contribution in terminal differentiation processes
remains poorly understood.
One such process is monocyte (MO)-to-osteoclast (OC)
differentiation. OCs are giant, multinucleated cells that de-
grade bone [2] and differentiate from monocytic progeni-
tors under inflammatory conditions. Their deregulation is
associated with several diseases, either through deficient
function that results in osteopetrosis [3] or aberrant hyper-
activation that gives rise to generalized bone loss in osteo-
porosis [4] and rheumatoid arthritis [5]. Moreover, OCs
cause bone complications in multiple myeloma [6] and in
cancer metastasis, including prostate and breast cancers
[7]. OCs differentiate from MO/macrophage progenitors
[8] after macrophage colony-stimulating factor (M-CSF) [9]
and receptor activator of nuclear factor kappa-B ligand
(RANKL) [10] stimulation. In vitro generation of OCs from
peripheral blood MOs allows differentiation to be studiedral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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otherwise be challenging [11]. During osteoclastogenesis,
progenitor cells fuse, reorganize their cytoskeleton [12]
and activate the gene expression profile necessary for bone
destruction. Several signaling pathways activate nuclear
factor-kappa B (NF-κB), mitogen-activated protein kinase
(MAPK) and c-Jun [13], which coordinately turn on
NFATc1 [14], the osteoclastogenesis master transcription
factor. NFATc1 acts in conjunction with PU.1 and MITF
[15], activating OC-specific genes such as those encoding
tartrate-resistant acid phosphatase (TRAP or ACP5) [16],
cathepsin K (CTSK) [17], dendritic cell-specific transmem-
brane protein (DC-STAMP or TM7SF4) [18], matrix
metallopeptidase 9 (MMP9) [19] and carbonic anhydrase
2 (CA2). Most importantly, other genes like CX3CR1, a
MO-specific gene, and TNFAIP3, a deubiquitinating pro-
tease that mediates TRAF6 degradation and impairs
NF-κB activation [20], need to be silenced during OC dif-
ferentiation. It is not well understood how the silencing
program is established during MO-to-OC differentiation.
The importance of miRNAs in OC differentiation has
been established through the observation that knock-out
models for the miRNA processing machinery impair OC
formation and reduced expression of TRAP and NFATc1
[21]. In addition, silencing of miRNAs, such as miR-29b
[22] and miR-124 [23], is essential for the upregulation of
pro-osteoclastic genes.
In this study, we investigated the role of miRNAs in es-
tablishing and maintaining a repressive program during
OC differentiation. To this end, we performed high-
throughput miRNA expression profiling of human
peripheral blood MOs before and 2 and 20 days after
stimulation with RANKL and M-CSF. We identified dif-
ferent dynamics in miRNA expression changes. Two
miRNA clusters, miR-212/132 and miR- 99b/let-7e/
125a, are highly upregulated during the early stages of
osteoclastogenesis. Functional analysis of these miRNAs
revealed that their depletion impairs proper OC differenti-
ation. Interestingly, these miRNAs target MO-specific and
anti-inflammatory genes that are downregulated during
differentiation, such as TNFAIP3, IGF1R, THBS1, ITGA4,
IL15 and PTGS2. We investigated the potential involve-
ment of the NF-κB transcription factor in the upregulation
of these miRNAs. We demonstrated the direct association
of p65 NF-κB with the transcription start site (TSS) of
these miRNA clusters. Most importantly, we found that
the pharmacological inhibition of the p65 subunit of
NF-κB or its depletion results in impaired overexpres-
sion of these miRNAs and affects the downregulation of
their targets. Our results demonstrate the direct relation-
ship between p65 NF-κB and miRNA-mediated repression
of several MO-specific and anti-inflammatory genes that is
key for proper osteoclastogenesis and reveal novel potential
pathways for therapeutic intervention in the treatment ofbone complications in diseases such as rheumatoid arthritis
and bone metastases.
Results
The miRNA expression profile changes drastically during
osteoclastogenesis
To determine the dynamics of miRNA expression during
human osteoclastogenesis, we first generated three sets of
matching samples corresponding to peripheral blood
MOs (CD14+ cells), MOs 48 hours after RANKL/M-CSF
treatment, and mature OCs obtained from the same sets
of MOs, 21 days after RANKL/M-CSF stimulation. The
quality of the OCs was confirmed microscopically by the
presence of three or more nuclei in TRAP-positive cells
and the formation of the actin ring (Figure 1A). At the
molecular level, we confirmed the upregulation of osteo-
clastic markers (CA2, CTSK, MMP9, ACP5/TRACP and
TM7SF4/DCSTAMP) and the silencing of the MO-
specific gene CX3CR1 (Figure 1B). We then performed
miRNA expression profiling during the differentiation of
MOs to OCs using the three sets of samples. Statistical
analysis of the combined expression data from three bio-
logical replicates showed 115 miRNAs that were differen-
tially expressed at one or more of the times analyzed
(Figure 1C; Additional file 1). miRNAs displayed different
expression profiles over time that enabled them to be clas-
sified into eight groups (Figure 1C) according to the com-
bination of upregulation or downregulation at the initial
or late stages of OC differentiation. Of particular interest
were the miRNAs whose expression increased rapidly in
the initial stages (groups I, V and VI; Figure 1C), regardless
of their subsequent changes over time. miRNAs that be-
come upregulated immediately after M-CSF and RANKL
stimulation are potentially more important for the differ-
entiation process than for the function of fully differenti-
ated OCs. miRNAs within two clusters ranked top in
terms of the coefficient of change and relative expression
levels, specifically miR-99b/let-7e/125a (group I, average
fold change = 49.4 between MOs and 48 h post-MCSF/
RANKL stimulation) and miR-212/132 (group VI, average
fold change = 50.57 between MOs and 48 h post-MCSF/
RANKL stimulation) (Figure 1D). Several other activated
miRNAs identified in our analysis have already been de-
scribed in human and mouse experiments concerning OC
differentiation (Figure 1C) like miR-124, a negative regula-
tor of NFATc1 expression [23], and miR-155, also upregu-
lated in bone marrow macrophage-derived OCs [24,25].
We confirmed the overexpression of all the miRNAs
within the miR-99b/let-7e/125a and miR-212/132 clusters
using quantitative RT-PCR (qRT-PCR) (Figure 1E). This
analysis also confirmed that individual miRNAs from each
of the two clusters do not reach the same expression
levels. For example, miR-99b and miR-125a levels are in-
creased by 300-fold and 100-fold respectively, whereas
Figure 1 MicroRNA expression profiling during monocyte-to-osteoclast differentiation. (A) Validation of the presence of OCs by TRAP and
phalloidin staining, showing the presence of TRAP activity/multiple nuclei and the actin ring, respectively. (B) Molecular characterization of OC
differentiation. Several OC markers are upregulated (CA2, CTSK, MMP9, ACP5/TRAP, and TM7SF4/DCSTAMP), and the MO marker CX3CR1 is silenced. Data for
MOs, MOs 48 h after M-CSF and RANKL treatment and OCs at 21 days are presented. RPL38 gene expression levels were used for normalization. Error bars
correspond to the standard deviation of three individual measurements. (C) Heatmap showing expression array data from the miRNA expression
screening. miRNAs were subdivided into eight groups (I to VIII) according to their expression profile (diagram); the number of miRNAs in each group is
indicated inside the expression dynamics diagram. Scale shown at the bottom, whereby normalized expression units ranges from -1 (blue) to +1 (red).
(D) Representation of the genomic distribution of miR-99b/125a/let7e and miR-132/212 clusters, including the TSS (indicated with an arrow). (E)
Validation of array data by quantitative PCR in independent biological replicates. Analysis in MOs, MOs incubated 48 h with RANKL/M-CSF and fully
differentiated OCs. Data normalized with respect to miR-103. (F) Expression dynamics of the indicated miRNAs during OC differentiation, also
normalized with respect to miR-103.
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This strongly suggests that miRNAs in these clusters are
regulated not only transcriptionally but also post-
transcriptionally during MO-to-OC differentiation, as it
has previously been observed for other miRNAs in other
differentiation programs [26]. To refine the expression dy-
namics of these miRNAs during the differentiation
process further, we generated a time course of osteoclasto-
genesis from three different healthy donors, and checked
the miRNA levels at several times during the entire differ-
entiation process. The two clusters showed different dy-
namics when we analyzed their expression levels over
time. Specifically, after RANKL/M-CSF stimulation, the
miR-99b/let-7e/125a cluster miRNAs underwent rapid
overexpression during the first four days and the levels
remained stably high until day 21 (Figure 1F, top). In con-
trast, miR-212/132 cluster miRNAs peaked at day 3,
displaying an increase of around 50-fold (miR132) to 170-
fold (miR-212), followed by an approximately 5-fold drop
(Figure 1F, bottom). This suggests that the functions of
miR-132 and miR-212 are involved in the early events of
osteoclastogenesis, since their expression levels are tightly
regulated and constrained to the first four days of
differentiation.
Inhibition of miRNAs within the miR-99b/let-7e/125a and
miR-212/132 clusters impairs osteoclastogenesis
To investigate the role of the individual miRNAs within
the two aforementioned clusters in OC differentiation,
we performed loss of function experiments. We trans-
fected primary MOs with specific inhibitors or antago-
mirs for each of the individual miRNAs contained in the
miR-99b/let-7e/125a and miR-212/132 clusters. In these
experiments, transfections with miRNA inhibitors were
performed simultaneously with RANKL/M-CSF stimula-
tion. We collected samples at 4 days. Then we tested the
expression of OC markers to assess the impact of deplet-
ing these miRNAs on the differentiation process. Simul-
taneously, we checked the efficiency of transfection by
flow cytometry of cells transfected with a control antag-
omir fluorescein-conjugate, recording efficiencies of 93%
and 97.6% depending on the reagent used for transfec-
tion (Figure 2A). qRT-PCR analysis revealed that indi-
vidual inhibition of each of the miRNAs within the two
clusters results in a delay and decrease in the levels of
OC markers like ACP5, CA2, CTSK and MMP9
(Figure 2B) at 4 days after RANKL/M-CSF stimulation.
An opposite effect was observed for the MO-specific
gene CX3CR1 with miR-99b and miR-125a (Figure 2B).
We also performed double-transfection experiments
with two combinations of miRNA inhibitors, containing
two miRNAs within each cluster. In these experiments
with two miRNA inhibitors we observed higher inhib-
ition of OC markers than in single transfections(Figure 2C), further demonstrating the functional role of
these miRNAs in the proper differentiation of OCs.
We then investigated the effects of depleting these
miRNAs on the acquisition of two essential OC mem-
brane proteins, CCR1 [27] and TM7SF4/DCSTAMP [28]
(Figure 2D). Flow cytometry analysis of these two sur-
face markers revealed that the depletion of any of the
individual miRNAs within the two clusters decreases
their levels 4 days after RANKL/M-CSF stimulation.
Finally, we tested whether depletion of these miRNAs
impacts the ability of MOs to fuse and form OCs follow-
ing RANKL/M-CSF stimulation. To this end, we per-
formed TRAP staining 4 days after RANKL/M-CSF
treatment on cells transfected with power inhibitors for
each of the miRNAs, when the first multinucleated OCs
start to be apparent. We observed a delay in OC forma-
tion in all cases, proving the relevance of these miRNAs
for the differentiation and fusion in TRAP+ OCs
(Figure 2E). These effects were less obvious at longer dif-
ferentiation times; however, this is not surprising given
the medium/long-term instability of antagomirs trans-
fected into cells. In summary, all these results indicate
that the high levels of the miRNAs from these two clus-
ters are necessary for proper differentiation of OCs.
Upregulated miRNAs target monocyte-specific and
immunomodulatory genes that need to be silenced
during osteoclastogenesis
Our results demonstrated that the miRNAs within the
most strongly activated miRNA clusters have a func-
tional effect on OC differentiation when inhibited in
MOs, as reflected by the decrease and delay in the up-
regulation of OC markers, including OC-specific surface
proteins, as well as in the ability to form multinuclear
cells. To identify the targets of these miRNAs, we re-
trieved a list of putative targets using miRWalk [29],
which contains prediction databases like TargetScan
[30], miRDB [31] and others, as well as information
about validated targets. We then linked the list of poten-
tial targets with previously reported high-throughput
data on expression changes during OC differentiation
[32], assuming an inverse relationship between the levels
of a given miRNA and the expression levels of its tar-
gets. For this analysis, we imposed the criteria that the
targets should be predicted by at least four databases
(Figure 3A) and that downregulation was defined as a
minimum 0.5-fold change. Applying these conditions we
identified a number of putative downregulated targets
for each overexpressed miRNA (Additional file 2). We
then used the Database for Annotation, Visualization
and Integrated Discovery (DAVID) to identify functional
categories. This tool revealed a highly significant enrich-
ment of categories related to the immune system
(Figure 3B), including immune system development
Figure 2 (See legend on next page.)
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Figure 2 Influence of miRNAs in modulating monocyte-to-osteoclast differentiation. (A) Quantification by flow cytometry of the transfection
efficiency using a fluorescent control power inhibitor or antagomir. (B) Functional effect of miRNA inhibition using power inhibitors (or antagomirs) for
the individual miRNAs in the miR-99b/125a/let7e and miR-132/212 clusters on CA2, CTSK, MMP9, ACP5 and CX3CR1 expression levels 4 days after
M-CSF/RANL stimulation. Quantification was done using qRT-PCR with specific primers for each gene and using the RPL38 gene for normalization. (C)
Functional effect of miRNA inhibition using double transfections with power inhibitors for two miRNAs within the miR-99b/125a/let7e and miR-132/
212 clusters. Quantification was carried out using qRT-PCR with specific primers for each gene and using the RPL38 gene for normalization. (D) Effect
of miRNA inhibition on the levels of surface markers CCR1 and TM7SF4. A bar diagram summarizing the results of the individual inhibition of each
miRNA of the two clusters is presented. Also, a plot of the fluorescence-activated cell sorting (FACS) analysis is presented. (E) Effect of miRNA inhibition
on the ability of cells to differentiate in OCs. Cells were arrested at 4 days after inducing differentiation. OCs were stained with TRAP. Cells with three or
more nuclei were counted as OCs. In the images, multinuclear OCs are indicated with a red arrow. On the right, a bar diagram showing the percentage
of OCs under each condition (center) and a bar diagram showing the number of cells with two, three or four or more nuclei under each condition
(right). Error bars correspond to the standard deviation of three independent measurements; *corresponds to P-value <0.05; **means P-value <0.01.
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3.04 E-11). We identified a number of critical factors
from among these (Figure 3C). For instance, miR-99b
was found to target the 3′ UTRs of IGF1R, miR-125a
targeted ETV6, TNFAIP3 and CX3CR1, and let7e
targeted TNFAIP3 and ITGA4. In the case of the miR-
NAs in the miR-212/132 cluster, miR-212 was found to
target CX3CR1 and HBEGF, and miR-132 targeted IRF1
and NR4A2. Some of these genes are also silenced by
other mechanisms during OC differentiation. Two ex-
amples are the MO-specific gene CX3CR1 and the anti-
inflammatory gene TNFAIP3, which are rapidly silenced
after MCSF/RANKL stimulation, and their promoters
are hypermethylated [33].
To validate the putative targets, we performed lucifer-
ase reporter assays using a vector containing the renilla
luciferase coding region plus the wild type or a mutant
form (Mut) of the putative 3′ UTR target sites of each
potentially targeted gene. We carried out these assays in
HeLa cells, in which we had previously estimated the
expression of high levels of miRNAs of the miR-99b/let-
7e/125a and miR-212/132 clusters. These assays con-
firmed that miR-99b targets IGF1R, miR-125a targets
TNFAIP3, and let-7e targets ITGA4 and THBS1. On the
other hand, miR-132 targets PTGS2, and miR-212 also
targets PTGS2 and IL15 (Figure 3D).
To obtain further evidence of the in vivo effect of the
miRNAs on their putative targets, we performed qRT-
PCR and western blotting in MOs transfected with each
of the miRNA inhibitors. In the case of the miR-99b/let-
7e/125a cluster, inhibition of miR-99, miR-125a and let-
7e resulted in the specific upregulation of IGF1R,
TNFAIP3 and IGF1R, and of ITGA4 and THBS1, re-
spectively. With respect to the miR-212/132 cluster, in-
hibition of miR-132 and miR-212 gave rise to the
upregulation of PTGS2 and the inhibition of miR-212 re-
sulted in the upregulation of IL15 (Figure 3E). We also
observed crossover effects between some miRNAs and
targets. For instance, inhibition of miR-99b and miR-
125a also affected PTGS2, which was not validated in lu-
ciferase assays but also contains putative recognitionsites at its 3′ UTR for miR-99b and miR-125. We ob-
served increased mRNA and protein levels for some of
these targets in double transfection experiments with
antagomirs (Figure 3F). Together with the luciferase as-
says, all these results confirmed the essential role of the
miRNAs in the downregulation of these genes during
OC differentiation.
Changes in the miRNA cluster expression levels in related
inflammatory-driven monocyte differentiation processes
We also investigated whether the observed miRNA expres-
sion changes occurring in OC differentiation constitute a
more general regulatory mechanism also operating in an-
other two related differentiation processes involving MOs,
specifically MO-to-dendritic cell differentiation and MO-to-
macrophage differentiation. These two processes are trig-
gered following stimulation with granulocyte-macrophage
CSF/IL4 or granulocyte-macrophage CSF alone (Figure 4A).
Analysis of the expression changes of all miRNAs within the
miR-99b/let-7e/125a and miR-212/132 clusters showed
these are common to all three processes (Figure 4B). Specif-
ically, we observed that all these miRNAs increased more
markedly in macrophages than in dendritic cells, suggesting
a bias towards the ability to generate a strong NF-κB-
mediated response, such as TLR4-initiated signals occurring
in inflammatory macrophages. Given the negative relation-
ship between these miRNAs and the regulation of their tar-
gets, it is feasible that they have a key role in the extinction
of mRNAs that are characteristic of a less inflammatory
prone state. This prompted us to investigate the relationship
between the increase in these miRNAs and the expression
levels of their validated targets in MO-to-dendritic cell and
MO-to-macrophage differentiation. We also noted a de-
crease in the mRNA levels of TNFAIP3, ITGA4, THBS,
IL5, and PTGS2 during the three differentiation pro-
cesses (Figure 4C). The only exception was IGF1R,
which appeared to increase over time in OC and den-
dritic cell differentiation, consistent with the findings of
others [34]. This could perhaps be due to the predomin-
ant effect of other regulatory mechanisms, probably at
the transcription level (Figure 4C). In this case, the
Figure 3 (See legend on next page.)
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Figure 3 Analysis of miRNA targets. (A) Venn diagram summarizing the rationale for selecting putative miRNA targets by combining the lists
generated with prediction algorithms with those generated from expression datasets (1,858 genes with a fold change <0.5). (B) Gene Ontology (GO)
enrichment analysis of putative miRNA targets from the previous analysis. (C) Summary of putative targets and their corresponding miRNA matches
among the miR-99b/125a/let7e and miR-132/212 clusters. (D) Luciferase assays of HeLa cells cotransfected with different luciferase reporter psiCheck2
constructs containing the 3′ UTR of putative targeted transcription factors (wild type (WT) or mutant (Mut) forms). (E) Effects on validated targets of the
single transfection with miRNA power inhibitors in MOs 4 days after being stimulated with RANKL/M-CSF, as assessed by qRT-PCR and western blotting.
Expression data are relative to the levels obtained for the samples transfected with control power inhibitor or antagomir (a-miR) and are normalized to the
RPL38 gene. Protein data have been normalized against α-tubulin, using the sample transfected with the control power inhibitor as a reference. At the
bottom, quantification of the levels of protein relative to the control for each antagomir. (F) Effects on validated targets of the double transfection with
miRNA power inhibitors in MOs 4 days after being stimulated with RANKL/M-CSF, as assessed by qRT-PCR and western blotting. Data analyzed as above.
Error bars correspond to standard deviation of three independent experiments; *corresponds to P-value <0.05; **means P-value <0.01; ***means
P-value < 0.001.
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related more to fine-tuning regulation in order to
achieve the proper levels of this protein instead of
blocking the expression of it.A direct role for NF-κB in the upregulation of miRNAs?
Our results supported the notion that miRNAs play a
role in the efficiency of OC differentiation and enabled
us to identify two upregulated miRNA clusters whose
participation in downregulating genes is key to this
process. As explained above, MO-to-OC differentiation
is induced by RANKL, which ultimately stimulates NF-
κB, a transcription factor once it has been translocated
into the nucleus. NF-κB acts in concert with PU.1, Jun
and the OC-specific transcription factor NFATc1. NF-
κB helps regulate many OC-specific genes. The tran-
scription factor NF-κB is also likely to participate in
shutting down MO-specific genes through the activa-
tion of miRNAs. To explore the potential involvement
of NF-κB in the changes in miRNAs during MO-to-OC
differentiation, we first investigated the enrichment of
the consensus binding site for the p65 NF-κB subunit in
a window of 500 bp upstream and downstream of the
TSS of the miRNAs (determined from the miRStart
database) [35]. This analysis showed that the p65 NF-κB
consensus binding site is present in the majority of
miRNA TSSs, including the miRNAs within the miR-
99b/let-7e/125a and miR-212/132 clusters (Figure 5A).
We then investigated the presence of p65 NF-κB around
the TSSs of these two miRNA clusters by performing
chromatin immunoprecipitation (ChIP) assays with
anti-p65 antibodies in MOs before and 48 h and 96 h
after induction with RANKL/M-CSF. We also used
primers near the TSS of CCL5 as a positive control. We
noted specific enrichment of p65 at 48 h and 96 h after
RANKL/M-CSF stimulation in the two upregulated
miRNA clusters (Figure 5B), demonstrating a direct as-
sociation of NF-κB p65 with the encoding sequence of
the upregulated miRNAs. We also found that p65
bound near the TSSs of other miRNAs, such as miR-34a(Figure 5B), suggesting that this may be a general mech-
anism of miRNA upregulation in OC differentiation.
To investigate the involvement of the NF-κB pathway
in the activation of these miRNAs in greater depth, we
treated MOs with two NF-κB inhibitors, Bay 11-7082
and sodium aurothiomalate (SATM), and investigated
the effects on the expression of the aforementioned miR-
NAs following induction by RANKL/M-CSF. SATM
inhibits the activity of IκB kinase by modifying cysteine
residues within its catalytic domain. Bay 11-7082 select-
ively and irreversibly inhibits the tumor necrosis factor-α-
inducible phosphorylation of IκBα, resulting in reduced
expression of NF-κB and adhesion molecules. Both inhibi-
tors eventually reduce the levels of phosphorylated Ser536
of p65, which correspond to its active form. To test the
toxicity of these two inhibitors, we first performed MTT
assays over a wide range of concentrations with primary
MOs (not shown), and selected 10 μM for Bay 11-7082
and 100 μM for SATM. Consistent with a relevant role of
the NF-κB pathway in the activation of these miRNAs, we
observed that phosphorylation of p65 increases following
RANKL/M-CSF stimulation of MOs (Figure 5C). Under
our conditions we observed potent inhibition of p65, as
reflected by the reduced levels of phospho-Ser536 p65, es-
pecially at 2 days, whereas at 4 days the inhibitory effects
of Bay 11-7082 were significantly reduced, perhaps due to
its instability in the culture medium (Figure 5C). We then
investigated the effects of these two inhibitors on miRNA
expression. Both inhibitors decreased expression of upreg-
ulated miRNAs (Figure 5D), reinforcing the notion of the
direct role of NF-κB in mediating their upregulation. Con-
sistent with the results obtained with the western blotting
(Figure 5C), the reduction in miRNA upregulation was
more obvious only at 2 days, whereas at 4 days the miR-
NAs of cells treated with Bay 11-7082 had reached the
levels of cells treated with the vehicle. As mentioned
above, this is perhaps due to the stability of the inhibitors
in the culture medium, which are added only at the begin-
ning. It could also be due to the contribution of additional
regulatory mechanisms that could be compensating for
the inhibition of the NF-κB pathway. We also checked the
Figure 4 Comparison of changes in the expression levels of the miRNAs within the miR-99b/125a/let7e and miR-132/212 clusters during
osteoclast differentiation, and changes during monocyte-to-macrophage and monocyte-to-dendritic cell differentiation. (A) Diagram depicting the
three differentiation models used in this experiment. GM-CSF, granulocyte-macrophage colony-stimulating factor. (B) Relative expression levels of the miRNAs
in matching samples of MOs (grey), immature dendritic cells (iDC, red), macrophages (green,) and monocytes stimulated with RANKL/M-CSF after 1, 2 and
4 days (immature OCs (iOC) (blue)). qRT-PCR data were normalized with respect to miR-103. (C) Relative expression levels of miRNA targets in the same set of
samples. qRT-PCR data were normalized with respect to the RPL38 gene. Error bars correspond to standard deviation of three independent measurements.
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targets. The two inhibitors reduced the levels of OC
markers, as determined by qRT-PCR after 4 days (Figure 5E).
Conversely, both SATM and Bay 11-7082 had an overall
positive effect on miRNA targets, providing evidence that
NF-κB helps repress these targets through miRNAs
(Figure 5F). We observed different effects in terms of which
of the two drugs was more effective or whether the effect
was more evident at 2 or 4 days, but we cannot discard the
occurrence of pleiotropic effects, or interference with other
regulatory mechanisms.
Therefore, as an unequivocal test of a potential causal re-
lationship between NF-κB and miRNA expression changes
in MO-to-OC differentiation, we investigated the conse-
quences of ablating p65 expression in MOs. To this end,we downregulated p65 levels in MOs using transient
transfection experiments with a small interfering RNA
(siRNA) that targets exon 11 of p65 (Figure 6A). In paral-
lel, we used a control siRNA. Following transfection we
stimulated differentiation with RANKL/M-CSF. Under
these conditions, we used qRT-PCR and western blotting
to check the effects on p65 levels 1, 2 and 4 days after
RANKL/M-CSF stimulation of MOs. By this means, we
were able to confirm that the level of p65 downregulation
was close to 50% (Figure 6A). siRNA-mediated downregu-
lation of p65 resulted in decreased binding of the miRNAs
to TSSs (Figure 6B). We also examined the expression
levels of these miRNAs following p65 depletion and found
that the RANKL/M-CSF-stimulated upregulation of the
miRNAs within the miR-99b/let-7e/125a cluster was
Figure 5 NF-κB dependence of miRNA expression changes. (A) Analysis of the presence of NF-κB subunit binding motifs (from TRANSFAC
database) in a 1,000-bp window centered around the estimated TSS of the miRNAs. (B) ChIP assays for selected miRNAs showing the binding of NF-κB
p65 near the TSS 2 and 4 days after RANKL/M-CSF stimulation of MOs. Each graph contains the relative enrichment of samples immunoprecipitated
with the anti-p65 antibody and an IgG as a control. MO samples were tested at 0, 2 and 4 days after M-CSF/RANKL stimulation. On top of each graph
the sequence analyzed is indicated. p65 putative binding sites are indicated with a blue dot. Primers used for amplification are indicated with arrows
around p65 binding sites. (C) Effects of the two NF-κB inhibitors (10 μM BAY 11-7082 (BAY11) and 100 μM sodium aurothiomalate (SATM) on the
phosphorylation levels of p65 as determined by western blotting. p65 and H3 total levels are used as controls. (D) Effects of two NF-κB inhibitors
(BAY11 and SATM) on the levels of miRNAs within the miR-99b/125a/let7e and miR-132/212 clusters measured by a time-course analysis of MOs
stimulated with RANKL/M-CSF. (E) Effects of treatment with BAY11 and SATM on markers of OC differentiation (ACP5, CTSK, TM7SF4, MMP9) as
estimated by qRT-PCR. Data relative to DMSO-treated samples and normalized with RPL38 expression levels. (F) Effects of treatment with BAY 11
and SATM on miRNA targets (IGF1R, TNFAIP3, ITGA4, THBS, IL15 and PTGS2) as estimated by qRT-PCR. Data are relative to DMSO-treated samples
and are normalized with respect to RPL38 expression levels. Error bars correspond to the standard deviation of three independent measurements;
*corresponds to P-value <0.05; **means P-value <0.01.
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Figure 6 NF-κB p65 has a direct role in changes in miRNA expression levels. (A) Diagram depicting the region of the p65 gene in exon 11
targeted by the siRNA used in this study. Effects of siRNA experiments on p65 levels in MOs stimulated with RANKL/M-CSF after 1, 2, and 4 days,
as analyzed by western blotting (bottom and central panels, normalized with respect to histone H3 levels) and qRT-PCR (left panel, relative to
RPL38 expression levels). (B) Effect of p65 depletion on its recruitment near the TSS of the coding sequence of the miRNAs, as demonstrated by
ChIP assays. The scheme on top of each graph depicts the region analyzed, indicating the p65 binding site (dot) and the primers used (arrows
around the p65 binding site). (C) Effects of p65 siRNA experiments on miR-99b, miR-125a and miR-let7e after 1, 2, and 4 days. Data relative to
miR-103 levels. (D) Effects of p65 downregulation on expression of genes upregulated during osteoclastogenesis (CTSK, MMP9, ACP5, TM7SF4).
(E) Effects of p65 downregulation on the levels of the miRNA targets TNFAIP3 and IGF1R. Expression data compared with MO samples treated with
control siRNA and values relative to RPL38 expression levels. Error bars correspond to the standard deviation of three independent measurements;
*corresponds to P-value <0.05; **means P-value <0.01.
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We also analyzed two miRNAs that are not direct p65 tar-
gets and observed no effect on their levels following p65
depletion (not shown).
We investigated the effects of depleting p65 on the ex-
pression of OC markers (ACP5, CTSK and TM7SF4) as
well as on miRNA targets. Whereas depletion of p65 led to
a decrease in the upregulation of OC markers (Figure 6D),
it resulted in an increase in miRNA targets (Figure 6E),
thereby confirming the direct role of p65 in regulating this
process.
Taken together, our findings are the first demonstra-
tion that NF-κB is directly associated with and activates
miRNAs that are essential for the regulation of critical
targets whose downregulation is essential for proper OC
differentiation.
Discussion
Our results provide novel insights into the role and mecha-
nisms of the fine-tuned control of expression and its relation
with inflammatory pathways in MO-to-OC differentiation.
Firstly, we identified a set of miRNAs that are required for
OC differentiation. Most importantly, these miRNAs target
and repress OC-inappropriate genes, including several MO-
specific and immunomodulatory genes. Secondly, our re-
sults reinforce the key role of the NF-κB transcription factor
as a direct regulator of miRNA upregulation, specifically fo-
cusing on the miR-99b/let-7e/125a and miR-212/132
clusters.
Screening miRNA expression changes at two points
during differentiation revealed different groups of miR-
NAs based on their expression profiles over time. Over-
all, our data show prevalent upregulation of miRNAs in
OC differentiation. Twenty-three miRNAs displayed fast
upregulation followed by sustained expression levels, 20
miRNAs had a rapid increase followed by downregula-
tion over a longer period following induction until day
21, and 26 miRNAs were upregulated only at later
stages. In contrast, there were significantly fewer miR-
NAs whose expression levels decreased over time. The
predominance of upregulated miRNAs may suggest that
their primary role is to repress or ensure the mainten-
ance of low levels of OC-inappropriate genes that couldalso be repressed through other mechanisms. Previous
data from our group have already shown this type of be-
havior in B cell-to-macrophage transdifferentiation [36].
Our analysis of the functional effects of the depletion of
the miRNAs within the miR-99b/let-7e/125a and miR-
212/132 clusters, as well the analysis of their targets,
shows that these molecules have a direct role in repres-
sing MO-specific and immunomodulatory genes like
TNFAIP3, IGF1R and IL15. In addition, loss of function
experiments using specific inhibitors for the above miR-
NAs influences the efficiency of osteoclastogenesis, as
determined by analyzing expression changes of standard
markers of OC differentiation at the RNA and protein
levels, the effects on validated targets of these miRNAs
and the ability of cells to fuse to yield multinucleated
OCs.
Our results suggest that fine-tuning modulation
through miRNA-mediated repression drives the monocytic
steady state program into an NF-κB-driven proinflamma-
tory differentiation program. This idea is reinforced by the
observation that the upregulation of these miRNAs also
occurs in related inflammatory-related monocytic differ-
entiation processes, including MO-to-dendritic cell differ-
entiation and MO-to-macrophage differentiation. MOs
are heterogeneous circulating progenitors that can either
patrol the resting endothelium or migrate into tissues in
response to inflammatory signals. Regulation of switching
between these different states requires the ability to re-
spond rapidly to changes that may include silencing of un-
desired response pathways, and the commitment to
ensure proper outcomes. miRNAs may contribute to this
process as a flexible regulatory mechanism, as it has been
described for miR146a and Relb pathway Ly6Chigh
inflammatory MO responses [37]. Our analysis on the
functional effects of depletion of the miRNAs within the
miR-99b/let-7e/125a cluster reveals a possible common
pathway of commitment into cells with strong NF-κB-
dependent responses, suggesting the targeting of the
anti-inflammatory molecule TNFAIP3 (A20) by these
microRNAs, which are upregulated in the conversion
into OCs, dendritics cells and macrophages. In addition,
depletion of the miR-212/132 cluster, as well as the ana-
lysis of their targets, shows that these elements have a
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could also shape inflammation.
Ly6Chigh MO conversion to Ly6Clo anti-inflammatory
macrophages with a restorative phenotype in murine hep-
atic fibrosis requires the upregulation of genes encoding
molecules of the anti-inflammatory macrophage program,
like CX3CR1, or with anti-fibrotic effects, like CD74 [38].
Interestingly, both genes are targeted by the miR-212/132
cluster in our MO-based differentiation models that con-
verge on the set-up of inflammatory or NF-κB programs
in different cell types. In addition, an immunosuppresive
role has also been assigned to the IGF1R-IGF1 axis, and
cord blood mononuclear cells as well as peripheral blood
mononuclear cells (PBMCs) treated with IGF1 show a de-
crease NF-κB binding activity [39]. Our results show that
IGF1R is targeted by miR99b and miR125a also suggesting
a coordinated shutdown of signal transduction that block
NF-κB pathways.
The second major conclusion of our study is the role of
NF-κB in directly upregulating the miR-212/132 and miR-
99b/let-7e/125a clusters, and perhaps other miRNAs.
Multiple genes implicated in inflammation, including pro-
inflammatory cytokines and their receptors, are under the
transcriptional control of the transcription factor NF-κB
[40]. A few reports have recently proved that NF-κB has a
direct role in regulating miRNA expression [41,42]. To
the best of our knowledge, however, this is the first report
demonstrating a direct role for NF-κB in miRNA control
in OC differentiation. NF-κB is a major target of RANKL,
which is used together with M-CSF to stimulate differenti-
ation of MOs into OCs. However, only a few direct NF-κB
targets have so far been described. For instance, it has
been shown that NF-κB cooperates with NFATc2 to in-
duce expression of NFATc1, with NFkB p50 and p65 being
recruited to the NFATc1 promoter within 1 hour of treat-
ment of OCPs with RANKL, resulting in transient auto-
amplification of NFATc1 expression, which is crucial for
OC formation [14]. To date, the participation of NF-κB in
this context had been restricted to an activator of genes
that are necessary for OC differentiation. Our findings re-
veal a novel role for NF-κB in activating miRNAs that re-
press the expression of OC-inappropriate genes that are
not required for differentiation. This perhaps includes not
only MO-to-OC differentiation, but also other related
MO-related differentiation processes where NF-κB plays a
key role. Several papers have come out showing regulatory
programs of Ly6Chigh inflammatory MOs/macrophages
versus Ly6Clo resting cells [37,38,43]. Nonetheless, unrav-
eling the mechanisms that delineate NF-κB versus other
programs in human MOs has been more difficult and this
issue is directly addressed by the present work.
The results of our study constitute the first clear evi-
dence that NF-κB directly regulates miRNAs, showing to-
gether with our findings on the miRNA targets and theimpact on OC differentiation that this is a novel mechan-
ism of gene repression of OC-inappropriate genes in this
differentiation process. In addition, our conclusions open
up possibilities for exploiting novel pathways for thera-
peutic intervention.
Conclusions
Our study on miRNA expression changes during MO-to-
OC differentiation reveals the occurrence of rapid upregu-
lation of two miRNA clusters. We have demonstrated that
miRNAs within these two clusters are necessary for MOs
to differentiate into OCs. These miRNAs are key to
repressing OC-inappropriate genes, including certain anti-
inflammatory genes, and are needed for proper OC differ-
entiation. We demonstrate that these changes and their
functional effects also occur in other MO differentiation
processes, indicating that these miRNAs are needed for
the downregulation of OC-inappropriate genes in MOs.
Most importantly, we demonstrate for the first time that
NF-κB directly regulates these miRNAs and is thus dir-
ectly implicated in the inhibition of the less differentiated
monocytic expression program.
Materials and methods
Differentiation of osteoclasts from peripheral blood
mononuclear cells
Human blood samples came from anonymous blood donors
through the Catalan Blood and Tissue Bank in Barcelona as
thrombocyte concentrates (buffy coats). The anonymous
blood donors received oral and written information about
the possibility that their blood would be used for research
purposes, and any questions that arose were then answered.
Before giving their first blood sample the donors signed a
consent form at the Banc de Teixits, which adheres to
the principles set out in the WMA Declaration of Helsinki.
The blood was carefully layered on a Ficoll-Paque gradient
(Amersham, Buckinghamshire, UK) and centrifuged at
2,000 rpm for 30 minutes without braking. After centrifu-
gation, PBMCs at the interface between the plasma and
the Ficoll-Paque gradient were collected and washed twice
with ice-cold phosphate-buffered saline, followed by
centrifugation at 2,000 rpm for 5 minutes. Pure CD14+
cells were isolated from PBMCs using positive selection
with MACS magnetic CD14 antibody (Miltenyi Biotec,
Bergisch Gladbach, Germany). Cells were then resus-
pended in α-minimal essential medium (α-MEM Gluta-
MAX Supplement, no nucleosides; Invitrogen, Carlsbad,
CA, USA) containing 10% fetal bovine serum, 100 units/ml
penicillin, 100 μg/ml streptomycin and antimycotic, supple-
mented with 25 ng/ml human M-CSF and 50 ng/ml soluble
hRANKL (PeproTech EC, London, UK). Depending on the
amount needed, cells were seeded at a density of 3 × 105
cells/well in 96-well plates, 5 × 106 cells/well in 6-well plates
or 40 × 106 cells in 10-mm plates and cultured for 21 days
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ged twice a week. The presence of OCs was checked by
TRAP staining using the Leukocyte Acid Phosphatase
Assay Kit (Sigma-Aldrich, St. Louis, Missouri, USA) ac-
cording to the manufacturer ? s instructions. Phalloidin/DAPI
staining enabled us to confirm that the populations were
highly enriched in multinuclear cells, some of which con-
tained more than 40 nuclei. We used several methods to
determine that on day 21 almost 85% of the nuclei detected
were ? osteoclastic nuclei? (in polykaryons; nuclei, rather
than cells, were quantified). OCs (TRAP-positive cells with
three or more nuclei) were also analyzed at the mRNA
level: upregulation of key OC markers (CA2, CTSK,
MMP9, ACP5/TRAP and TM7SF4/DCSTAMP) and down-
regulation of the MO marker CX3CR1 were confirmed.
Visualization of osteoclasts with phalloidin and DAPI
staining
Pure isolated CD14+ cells were seeded and cultured in
glass Lab-Tek Chamber Slides (Thermo Fisher Scientific,
Waltham, MA, USA) for 21 days in the presence of hu-
man M-CSF and human RANKL. OCs were then
washed twice with phosphate-buffered saline and fixed
(3.7% paraformaldehyde, 15 minutes). Cells were perme-
abilized with 0.1% (V/V) Triton X-100 for 5 minutes and
stained for F-actin with 5 U/ml Alexa Fluor® 647-
Phalloidin (Invitrogen). Cells were then mounted in
Mowiol-DAPI mounting medium. Cultures were visual-
ized by confocal laser scanning microscopy (Leica TCP
SP2 AOBS confocal microscope).
Flow cytometry
Cells were stained with fluorochrome-conjugated antibodies
against CCR1 (R&D Systems, reference FAB145A-100) and
TM7SF4 (R&D Systems, reference FAB7824-A) (Both anti-
bodies are from R&D Systems, Minneapolis, MN, USA) 0
and 4 days after RANKL/M-CSF stimulation. CCR1 and
TM7SF4 expression were monitored on a Gallios Flow Cyt-
ometer (Beckman Coulter, Pasadena, California, USA) and
analyzed by FlowJo software (Tree Star, Inc., Ashland,
Oregon, USA). All experiments were performed in triplicate
and bar graphs correspond to independent biological
samples.
MicroRNA expression screening and target prediction
Total RNA was extracted with TriPure (Roche, Basel,
Switzerland) following the manufacturer ?s instructions.
Ready-to-use miRNA PCR Human Panel I V2.R from Exi-
qon (reference 203608) was used according to the instruc-
tion manual (Exiqon, Vedbeak, Denmark). Total RNA
(30 ng) was used for each RT-PCR reaction. Paired samples
of MOs at 0 (MO), 2 (OC 48 h) and 21 (OC) days after M-
CSF and RANKL stimulation were obtained from three fe-
male healthy donors (aged 25 to 28 years), and wereanalyzed with a Roche LightCycler® 480 real-time PCR sys-
tem. Results were converted to relative values using the
inter-plate calibrators included in the panels (log2 ratios).
Average expression values of MO, OC 48 h and OC were
normalized with respect to the reference gene miR-103. A
t-test was then performed and differentially expressed miR-
NAs (fold change >2 or <0.5), with a significant P-value
(P < 0.05) in at least one of the comparisons, were selected
and represented on a heatmap. The raw expression data are
listed in full in Additional file 1. The array expression data
were validated in the samples used (validation set), and in a
larger cohort of samples obtained from independent donors
(replication set) using Exiqon microRNA LNA™ PCR primer
sets (hsa-miR-99b-5p, reference 204367; hsa-miR-125a-5p,
reference 204339; hsa-miR-132-3p, reference 204129; hsa-
miR-212-3p, reference 204170; hsa-miR-103a-3p, reference
204063).
To predict the potential targets of the deregulated miR-
NAs, we used the algorithms from several databases: Tar-
getScan, PicTar, PITA, miRBase, microRNA.org, miRDB/
MirTarget2, TarBase, miRecords and StarBase/CLIPseq.
Only targets predicted by at least four of these databases
were retained for further analysis.
Bioinformatics analysis of expression data
To compare the expression data with the methylation
data, we used CD14+ and OC expression data from the
ArrayExpress database [44] (accession EMEXP-2019)
from a previous publication [32]. Affymetrix GeneChip
Human Genome U133 Plus 2.0 expression data were
processed using the limma and affy packages from Bio-
conductor. The pre-processing stage was divided into
three main steps: background correction, normalization
and reporter summarization. We chose the expresso
function of the affy package for preprocessing. Thus, the
robust multi-array average (RMA) method was used for
background correction. Quantile normalization was
then done. We also introduced a specific step for PM
(perfect matchprobes) adjustment, using the PM-only
model-based expression index (option ? pmonly ? ). Fi-
nally, for the summarization step, the median polish
method was used. Next, variance filtering by IQR (inter-
quartile range) was carried out, taking 0.50 as the
threshold value. After preprocessing, data were analyzed
using the empirical Bayes moderated t-test available in
the limma statistics package. Expression data were vali-
dated by qRT-PCR.
Transfection of primary human monocytes with miRNA
inhibitors and p65 NF-κB siRNA
To perform the miRNA inhibitor experiments, we used
unlabeled miRCURY LNA™ microRNA Power inhibitors
to inhibit miR-99b (reference 4101513), miR-let-7e (ref-
erence 4103550), miR-125a (reference 4103094), miR-
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a control (Negative Control A, reference 199006) Exiqon,
Vedbaek, Denmark. Power inhibitors (5 or 10 nM) were
transfected into CD14+ MOs using HappyFect Transfec-
tion Reagent (Tecan, Weymouth, UK) or Lipofectamine
®3000 (Life Technologies). Cells were simultaneously incu-
bated in the presence of RANKL/M-CSF in the conditions
previously described. The efficiency of transfection was
quantified by flow cytometry using the 5′-fluorescein-la-
beled Negative Control A. For samples collected at 4 days
or after, we added a fresh aliquot of miRNA inhibitors
after 48 h. To silence p65, we used Silencer® Select Pre-
Designed siRNA (Life Technologies) against human RELA
(p65), targeting exon 11 (reference s11916) in parallel with
a Silencer® Select negative control in purified CD14+ MOs
in the presence of M-CSF, followed by stimulation with
RANKL (and M-CSF) 24 h after siRNA transfection. We
used Lipofectamine RNAiMAX Transfection Reagent
(Invitrogen) for efficient siRNA transfection. mRNA and
protein levels were examined by qRT-PCR and western
blotting 1, 2, and 4 days after siRNA transfection. These
experiments were performed with at least three biological
replicates.Luciferase assays
The putative miRNA binding sites in the 3′ UTRs of
IGF1R, TNFAIP3, ITGA4, THBS1, IL15, and PTGS2 were
amplified by PCR from genomic DNA derived from CD14
+ cells. The PCR products were cloned into pGEM®-T
Easy Vector (Promega, Madison, Wisconsin, USA) and
four to seven point mutations were introduced into each
target site by site-directed mutagenesis. Each of the frag-
ments containing the 3′ UTR of putative miRNA binding
sites was cloned into psiCHECK-2 vector (Promega).
293 T cells were cultured for 24 h and then co-transfected
using lipofectamine RNAimax with 10 ng of psiCHECK-2
vector containing wild-type or mutant 3′ UTR plus 50
nM of miRNA power inhibitors per well. The luciferase
analysis was performed 48 h later using the Dual-
Luciferase Reporter Assay (Promega). Primers to clone
the 3′ UTR of putative miRNA binding sites are listed in
Additional file 3.Chromatin immunoprecipitation assays
For ChIP assays, CD14+ cells 0, 2 and 4 days after treat-
ment with M-CSF and RANKL were crosslinked with 1%
formaldehyde and subjected to immunoprecipitation after
sonication. ChIP experiments were performed as de-
scribed elsewhere [33]. Analysis involved real-time qPCR.
Data are represented as the ratio of bound fraction to in-
put for each specific factor. We used a mouse monoclonal
antibody against the carboxyl terminus of human NF-κB
p65 (sc-372, Santa Cruz Biotechnology, Dallas, Texas,USA). Primer sequences are shown in Additional file 3.
Experiments included three biological replicates.
Quantitative RT-PCR and western blotting
RNA was isolated by TRIzol extraction (Invitrogen) and
reverse-transcribed using SuperScriptTM II Reverse Tran-
scriptase (Invitrogen). Primers for conventional and qRT-
PCR were designed using Primer3 v.0.4.0 (Table S1 in
Additional file 1). qRT-PCR was performed in triplicate
using LightCycler 480 SYBR Green Mix (Roche). PCR
reactions were run and analyzed using the LightCycler
480 II System (Roche). Expression values were normalized
against the expression of the endogenous gene controls
RPL38, HPRT1 and GAPDH. Primers are listed in
Additional file 3.
For western blots, protein lysates were generated and
western blotting performed using standard procedures
using antibodies against phospho-Ser536 p65 (Cell Sig-
naling, 3033 Danvers, Massachusetts, USA), p65 (Santa
Cruz Biotechnologies, sc-372), IGF1R (Abcam, ab32823,
Cambridge, UK), PTGS2 (Abcam, ab15191), TNFAIP3
(Abcam, ab92324), IL15 (Abcam, ab7213), ITGA4 (Abcam,
ab81280), THBS1 (Thermo Scientific, MA5-13398), α-
tubulin (Sigma, 1142) and total histone 3 (Abcam, ab1791).
Graphs and heatmaps
All graphs were created using Prism5 Graphpad (Graph-
Pad Software, San Diego, California, USA). Heatmaps
were generated from expression or methylation data using
the Genesis program (Graz University of Technology).
Data access
Raw data for microRNA expression profiling as obtained
following qRT-PCR amplification of Ready-to-use micro-
RNA PCR Human Panel I V2.R from Exiqon (reference
203608) is available in Additional file 1. It is also available
in NCBI? s Gene Expression Omnibus through GEO Series
accession number GSE63773.
Additional files
Additional file 1: Raw data of miRNA expression profiling following
quantitative RT-PCR (qRT-PCR) amplification of Ready-to-use microRNA
PCR Human Panel I V2.R from Exiqon (reference 203608) in a Roche
LC480 II corresponding to pure CD14+ cells (MOs), and these cells at
48 h and 21 d after RANKL/M-CSF stimulation from three anonymous
individuals (D1, D2 and D3). Data are as follows: RAW crossing point (Cp)
values as produced by the qPCR system (columns B, D, F, N, P, R, Z, AB, AD),
RAW concentration (Conc) as produced by the qRT-PCR system (columns C, E,
G, O, Q, S, AA, AC, AE), concentration values relative to miR103 (housekeeping)
levels (columns H, I, J, T, U, V, AF, AG, AH). The average of the three samples
for each cell type (MOs, OCs 48 h, OCs 21 d) (column K, W, AI), standard
deviation (column L, X, AJ).
Additional file 2: (A) Heatmaps corresponding to putative targets
for all miRNAs within the miR-99b/125a/let7e and miR-132/212
clusters using miRWalk. For a given prediction database (DIANAmT,
miRanda, miRDB, miRWalk, PICTAR4, PICTAR5, PITA, RNA22, TargetScan)
de la Rica et al. Genome Biology  (2015) 16:2 Page 16 of 17red corresponds to a positive match and blue indicates that it is not
predicted. Only those putative targets predicted with at least four
algorithms were used. (B) Overlap between the analysis with miRWAlk
and expression data [32], using those genes that are downregulated in
OC differentiation at least 0.5-fold. (C) Schematic representations of the
pairing between different miRNAs and the 3′ UTR of different putative
target genes.
Additional file 3: Primer sequences.
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